C9290 HCPCS Level II code: Injection, bupivacaine liposome, 1 mg
CMS terminated C9290: its last date of service was Dec 31, 2024. It stays here for looking up older claims; newer services need a current code.
Official description
C9290Injection, bupivacaine liposome, 1 mg
Short description: Inj, bupivacaine liposome
HCPCS · United States
Medicare details
The indicators CMS publishes with C9290 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Special coverage instructions apply
- Medicare pricing
- Statute
- Type of service
- Medical care
- BETOS category
- Other drugs
- Coverage statute
- 1833(t)
- Added
- Apr 1, 2012
- Terminated after
- Dec 31, 2024
Where C9290 sits
- 1C codesOutpatient prospective payment system
- 2Terminated C9290Injection, bupivacaine liposome, 1 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
Is HCPCS code C9290 still valid?
No. CMS terminated C9290; its last date of service was Dec 31, 2024. It is listed for looking up services from before then. Use a current code for newer services.
Does Medicare cover C9290?
CMS lists C9290’s Medicare coverage as “Special coverage instructions apply” and its pricing as “Statute”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside C9290
All C codesC9248Injection, clevidipine butyrate, 1 mgC9250Human plasma fibrin sealant, vapor-heated, solvent-detergent (artiss), 2 mlC9254Injection, lacosamide, 1 mgC9257Injection, bevacizumab, 0.25 mgC9275Injection, hexaminolevulinate hydrochloride, 100 mg, per study doseC9285Lidocaine 70 mg/tetracaine 70 mg, per patchC9293Injection, glucarpidase, 10 unitsC9300Injection, indigotindisulfonate sodium, 1 mgC9301Obecabtagene autoleucel, up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic doseC9302Injection, zanidatamab-hrii, 2 mgC9303Injection, zolbetuximab-clzb, 1 mgC9304Injection, marstacimab-hncq, 0.5 mg